Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Endocrinology | Ophthalmology | Journal

Back to Journal Articles

Drinking Linked to Worsened Visual Acuity in Diabetes

Last Updated: December 28, 2010.

 

But study finds no increase in risk for diabetic retinopathy among drinkers with type 2 diabetes

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Alcohol consumption by individuals with type 2 diabetes is associated with an increased risk for deterioration of visual acuity but not diabetic retinopathy, according to a study in the October issue of Diabetic Medicine.

TUESDAY, Dec. 28 (HealthDay News) -- Alcohol consumption by individuals with type 2 diabetes is associated with an increased risk for deterioration of visual acuity but not diabetic retinopathy, according to a study in the October issue of Diabetic Medicine.

Chee-Tin C. Lee, of the Institute of Metabolic Science in Cambridge, U.K., and colleagues analyzed a cohort of 1,239 older (aged 55 to 81 years) persons with type 2 diabetes who had participated in a sub-study of the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial. The researchers analyzed the association of self-reported wine, spirits, and beer consumption with the incidence of diabetic retinopathy and deterioration of visual acuity.

In a mean 5.5-years of follow-up, the researchers identified 182 participants with a two-step progression in the Early Treatment of Diabetic Retinopathy Study score, 640 with retinal vascular lesions, and 693 with visual acuity deterioration. Compared with no current alcohol consumption, current moderate consumption (defined as one to 14 drinks per week) was not associated with diabetic retinopathy or its progression; however, it was associated with higher risk of visual acuity deterioration (odds ratio, 1.83.)

"Alcohol consumption is associated with increased risk of deterioration of visual acuity, but not with retinopathy in individuals with type 2 diabetes," the authors write.

Several study authors disclosed financial ties to Servier, a co-sponsor of the ADVANCE Trial.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2010 HealthDay. All rights reserved.


Previous: AML Outcomes Improve With Gemtuzumab Ozogamicin Next: Oral Squamous Cell Carcinoma Prognostic Factors Identified

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2013
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.